SCG2 has been increasingly demonstrated to be highly expressed in colorectal carcinoma, renal carcinoma, melanoma, as well as other cancers (Fukumoto et al., 2023; Steinfass et al., 2023; Weng et al., 2022). This evidence concerns the gene SCG2 and renal carcinoma.